Saturday, June 3 & Sunday June 4, On-Site Press Briefings available Sunday 7AM & Monday 7AM
- LBA2: PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
- LBA3: Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‐mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
- LBA1: INDIGO: A global, randomized, double- blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
- LBA4: SWOG S1826, a Randomized Study of Nivolumab(N)-AVD Versus Brentuximab Vedotin(BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL).
- LBA5507: Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
- LBA3000: Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
- LBA7505: Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.
- LBA106: Phase 3 Results From CARTITUDE-4: Cilta-cel Versus Standard of Care (PVd or DPd) in Lenalidomide-Refractory Multiple Myeloma
LBA2: PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
LBA3: Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‐mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
LBA1: INDIGO: A global, randomized, double- blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
LBA4: SWOG S1826, a Randomized Study of Nivolumab(N)-AVD Versus Brentuximab Vedotin(BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL).
LBA5507: Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
LBA3000: Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
LBA7505: Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.
LBA106: Phase 3 Results From CARTITUDE-4: Cilta-cel Versus Standard of Care (PVd or DPd) in Lenalidomide-Refractory Multiple Myeloma
Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch mit Prof. Dr. med. Nadia Harbeck, München
MonarchE: Abemaciclib in der adjuvanten Brustkrebstherapie
Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch mit PD Dr. med. Rachel Würstlein
Behandlung von Nebenwirkungen der Brustkrebstherapie
Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch mit PD Dr. med. Rachel Würstlein
Unterbrechung der antihormonellen Therapie für Schwangerschaft bei Brustkrebs
Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch mit Prof. Thorsten Kühn, Esslingen
Lokoregionäre Brustkrebs-Therapie: EUROBREAST
Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch mit Prof. Dr. med. Wolfgang Janni, Ulm
Stellenwert von ctDNA
Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch mit Prof. Dr. med. Christoph Thomssen, Halle (Saale)
Carboplatin bei triple negativem frühen Brustkrebs
Mathias Warm, Köln-Holweide: Lokoregionäre Therapie - Deeskalation bei Brustkrebs
Achim Wöckel, Würzburg: Früher triple negativer Brustkrebs: Immuntherapie mit Pembrolizumab
Rachel Würstlein, München: Integrative (komplementäre) Therapien und Lebensstil beim Brustkrebs